Proteasome deubiquitinases as novel targets for cancer therapy

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• The ubiquitin-proteasome system (UPS) is crucial for cellular protein homeostasis and is dysregulated in cancer.
• Existing proteasome inhibitors, such as bortezomib, have shown efficacy but also limitations.
• Targeting deubiquitinase (DUB) activity within the UPS presents a novel therapeutic avenue.

Purpose of the Study:

• To review the potential of proteasome deubiquitinase inhibitors as anti-cancer agents.
• To discuss the mechanism of action of novel inhibitors like b-AP15.
• To highlight the advantages of DUB inhibitors over traditional proteasome inhibitors.

Main Methods:

• Review of existing literature on UPS, proteasome inhibitors, and deubiquitinases.
• Analysis of the mechanism of action of b-AP15, a novel 19S RP DUB inhibitor.
• Comparison of b-AP15 with bortezomib regarding efficacy and resistance mechanisms.

Main Results:

• The small molecule b-AP15 selectively inhibits USP14 and UCHL5, key DUBs of the 19S RP.
• Inhibition of these DUBs leads to the accumulation of ubiquitinated proteins and proteasome dysfunction.
• b-AP15 demonstrates anti-tumor activity in solid tumor models and is effective despite Bcl-2 overexpression.

Conclusions:

• Proteasome deubiquitinase inhibitors represent a promising new class of anti-cancer therapeutics.
• b-AP15's unique mechanism offers potential advantages over current proteasome inhibitors.
• Targeting DUBs could overcome resistance mechanisms and broaden therapeutic applications in oncology.